Ravid Doron

Dr. Ravid Doron

The Open University, Jerusalem, Southern, Israel
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2015 in Journal of Visualized Experiments
Verified
Journal Article
Open access
PDF file
RYRoni Yankelevitch-Yahav
Roni Yankelevitch-Yahav
MFMotty Franko
Motty Franko
AHAvrham Huly
Avrham Huly
Ravid DoronRavid Doron
Ravid Doron
This protocol describes the forced swim test, which is used for the study of depressive-like behavior in rodents. This procedure...

24 October 2018 in Journal of Visualized Experiments
Verified
Journal Article
Closed access
PDF file
OBOr Burstein
Or Burstein
Ravid DoronRavid Doron
Ravid Doron
Depression is a highly prevalent and debilitating condition, only partially addressed by current pharmacotherapies. The lack of response to treatment by many patients prompts the need to develop new therapeutic alternatives and to better understand the etiology of the disorder. Pre-clinical models with translational merits are rudimentary for this task. Here we present a protocol for the unpredictable chronic mild stress (UCMS) method in mice. In this protocol, adolescent mice are chronically exposed to interchanging unpredictable mild stressors. Resembling the pathogenesis of depression in humans, stress exposure during the sensitive period of mice adolescence instigates a depressive-like phenotype evident in adulthood. UCMS can be used for screenings of antidepressants on the variety of depressive-like behaviors and neuromolecular indices. Among the more prominent tests to assess depressive-like behavior in rodents is the sucrose preference test (SPT), which reflects anhedonia (core symptom of depression). The SPT will also be presented in this protocol. The ability of UCMS to induce anhedonia, instigate long-term behavioral deficits and enable reversal of these deficits via chronic (but not acute) treatment with antidepressants strengthens the protocol's validity compared to other animal protocols for inducing depressive-like behaviors.

15 November 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OBOr Burstein
Or Burstein
MFMotty Franko
Motty Franko
EGEyal Gale
Eyal Gale
AHAssaf Handelsman
Assaf Handelsman
SBSegev Barak
Segev Barak
Ravid DoronRavid Doron
Ravid Doron
Anhedonia is defined as a diminished ability to obtain pleasure from otherwise positive stimuli. Anxiety and mood disorders have been previously associated with dysregulation of the reward system, with anhedonia as a core element of major depressive disorder (MDD). The aim of the present study was to investigate whether stress-induced anhedonia could be prevented by treatments with escitalopram or novel herbal treatment (NHT) in an animal model of depression. Unpredictable chronic mild stress (UCMS) was administered for 4 weeks on ICR outbred mice. Following stress exposure, animals were randomly assigned to pharmacological treatment groups (i.e., saline, escitalopram or NHT). Treatments were delivered for 3 weeks. Hedonic tone was examined via ethanol and sucrose preferences. Biological indices pertinent to MDD and anhedonia were assessed: namely, hippocampal brain-derived neurotrophic factor (BDNF) and striatal dopamine receptor D2 (Drd2) mRNA expression levels. The results indicate that the UCMS-induced reductions in ethanol or sucrose preferences were normalized by escitalopram or NHT. This implies a resemblance between sucrose and ethanol in their hedonic-eliciting property. On a neurobiological aspect, UCMS-induced reduction in hippocampal BDNF levels was normalized by escitalopram or NHT, while UCMS-induced reduction in striatal Drd2 mRNA levels was normalized solely by NHT. The results accentuate the association of stress and anhedonia, and pinpoint a distinct effect for NHT on striatal Drd2 expression.

1 April 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Ravid DoronRavid Doron
Ravid Doron
DLDafna Lotan
Dafna Lotan
ZVZiv Versano
Ziv Versano
LBLayla Benatav
Layla Benatav
MFMotty Franko
Motty Franko
MRMoshe Rehavi
Moshe Rehavi
Anxiety disorders are a major public health concern worldwide. Studies indicate that repeated exposure to adverse experiences early in life can lead to anxiety disorders in adulthood. Current treatments for anxiety disorders are characterized by a low success rate and are associated with a wide variety of side effects. The aim of the present study was to evaluate the anxiolytic effects of a novel herbal treatment, in comparison to treatment with the selective serotonin reuptake inhibitor escitalopram. We recently demonstrated the anxiolytic effects of these treatments in BALB mice previously exposed to one week of stress. In the present study, ICR mice were exposed to post natal maternal separation and to 4 weeks of unpredictable chronic mild stress in adolescence, and treated during or following exposure to stress with the novel herbal treatment or with escitalopram. Anxiety-like behavior was evaluated in the elevated plus maze. Blood corticosterone levels were evaluated using radioimmunoassay. Brain derived neurotrophic factor levels in the hippocampus were evaluated using enzyme-linked immunosorbent assay. We found that (1) exposure to stress in childhood and adolescence increased anxiety-like behavior in adulthood; (2) the herbal treatment reduced anxiety-like behavior, both when treated during or following exposure to stress; (3) blood corticosterone levels were reduced following treatment with the herbal treatment or escitalopram, when treated during or following exposure to stress; (4) brain derived neurotrophic factor levels in the hippocampus of mice treated with the herbal treatment or escitalopram were increased, when treated either during or following exposure to stress. This study expands our previous findings and further points to the proposed herbal compound's potential to be highly efficacious in treating anxiety disorders in humans.

1 January 2014 in Life Sciences
Verified
Journal Article
Closed access
Ravid DoronRavid Doron
Ravid Doron
DLDafna Lotan
Dafna Lotan
NENili Einat
Nili Einat
RYRoni Yaffe
Roni Yaffe
AWAvigail Winer
Avigail Winer
MRMoshe Rehavi
Moshe Rehavi

1 June 2012 in Life Sciences
Verified
Journal Article
Closed access
Ravid DoronRavid Doron
Ravid Doron
DLDafna Lotan
Dafna Lotan
ARAnat Rak-Rabl
Anat Rak-Rabl
ARAdi Raskin-Ramot
Adi Raskin-Ramot
KLKaren Lavi
Karen Lavi
MRMoshe Rehavi
Moshe Rehavi